The progression of colon, lung, breast, head and neck, prostate and ovarian cancers have all been reported to be mediated, at least in part, by GPCR-EGFR crosstalk [143], indicating that combined GPCR and EGFR inhibition could induce more pronounced clinical responses. The gene discussed is FZD4; the disease is ovarian carcinoma.